MetLife, Inc. (MET): what the price requires

At today's price, MetLife, Inc. (MET) is priced for 17.5% return on equity. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.

Generated: 2026-07-14 · Exported: 2026-07-16 · Source: https://boothcheck.com/report/MET

Headline

FieldValue
TickerMET
CompanyMetLife, Inc.
Current price$93.01/sh
CompositionGroup Benefits 55% / Retirement and Income Solutions (RIS) 43% / MIM (MetLife Investment Management) 2%

What The Price Requires (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basisfinancials
Elite ROE must persist for19.6y before normalizing (held at the 17.4% elite tier)
Perpetuity-equivalent ROE17.5%
Return on equity now11.2%
ROE gap+6.3pp
Price-to-book2.19x

Solve inputs: computed at a 10.2% cost of equity; ROE searched up to the 17.4% ROE ceiling; each 1pp moves the implied horizon ~5 years.

How unusual the bet is: elevated

ReferenceValue
vs own history+2.55σ
cohort percentile (of 80 peers)63
sustained it ~10 years at this level55%
implied end-window share0%

Valuation X-Ray

The price is justified by relative-multiple and growth-DCF; earnings-power land below the price.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset1.34x3expensive
Earnings1.66x1expensive
Relative0.90x1justifies
Growth1.24x1expensive

Families that justify the price: Relative, Growth Families that call it expensive: Earnings

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 9.2%); the inversion above states its own rate.

Per-Model Detail (n=6)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth——no—
Bank Fair Value (P/TBV)—$46.212.01xyesTBVPS $27.08 × 1.71x (ROE (TTM) 13.2% / CoE 9.3%, g=5.0% (sustainable: 65% retention × ROE, 5% cap; not the terminal-growth assumption), credit 1.45% allowance/loans → ×0.96, NPL 3.14% → ×0.92)
Relative ValuationRelative$103.230.90xyesP/E 12.76x (blended: static sector reference 11x + trailing (TTM) 17x), scenarios: 10.7x / 12.8x / 14.8x (bear / base = reference held flat / bull), EV/EBITDA 10x
Simple DDMGrowth——no—
Two-Stage DDMGrowth——no—
Simple Excess ReturnAsset$59.671.56xyesBV/sh $41.67, ROE (TTM) 13.2%, ke 9.3%
Two-Stage Excess ReturnAsset$70.771.31xyes5yr excess ROE then converge to ke=9.3%
Discounted Future Market CapGrowth$75.251.24xyesRev $77.6B, growth 5% (input: historical growth; tapered), Terminal P/S: 0.7x / 0.8x / 0.9x (bear / base = today's held flat / bull, cap 8x)
Growth-Adjusted P/ERelative——no—
Margin TrajectoryGrowth——no—
Earnings Power ValueEarnings——no—
Residual IncomeAsset——no—
Graham NumberAsset$69.621.34xyes√(22.5 × EPS $5.17 × BVPS $41.67) — Graham's conservative floor
EV/EBITDA RelativeRelative——no—
FCF YieldEarnings——no—
SBC-Adj FCF YieldEarnings——no—
Ben Graham FormulaEarnings$4.3321.48xyesEPS $5.17 × (8.5 + 2×-5.0%) × (4.4 / 5.3%) (excluded from median)
ROIC-Justified P/BAsset——no—
P/Sales SectorRelative——no—
PEG Fair ValueRelative——no—
Earnings YieldEarnings$55.891.66xyesEPS $5.17 / required return 9.3% (Rf 4.3% + ERP 5.0%)
Funds From Operations MultipleRelative——no—
Clinical Phase NPVGrowth——no—
MertonAsset——no—
V5 Mechanical———no—

Solvency

FieldValue
Share count CAGR (buyback)-5.7%

Deposit/float-funded balance sheet: debt is funding, not corporate leverage, and GAAP operating cash flow follows loan flows. Net-debt, interest-coverage, and cash-burn lenses do not apply. The solvency frame for a financial is regulatory capital and payout capacity (CET1, stress buffer, dividends plus buybacks against earnings).

Bullet Takeaways

MetLife is a global life and group insurer, led by Group Benefits (about 55% of the business) and Retirement and Income Solutions, executing a multi-year plan called New Frontier that targets double-digit adjusted EPS growth and a 15% to 17% adjusted return on equity. Q1 2026 delivered adjusted EPS of $2.42, up 23%, with adjusted ROE at 17%, the top of the range.

What the standard models miss is the per-share machine. The company is buying back stock aggressively (the share count is shrinking about 5.7% a year), which converts a steady-ROE insurer into a double-digit EPS grower without needing the underlying business to grow that fast.

At about $86 the price reads as supported by asset-based and relative-multiple value while the earnings-power and growth-DCF frames say expensive, an elevated but value-anchored profile. The stock trades around 8.5 times forward earnings.

Bull Case

Start with what a generic valuation model misses about MetLife, because the gap between the screen and the business is the whole opportunity. Standard discounted-cash-flow and earnings-power frames struggle with a life insurer: the reported earnings are noisy with actuarial assumption changes and investment marks, and the balance sheet is float, not corporate capital. What those models cannot see is the per-share compounding engine. MetLife is returning capital with conviction, shrinking the share count about 5.7% a year, which means even a steady-ROE insurer becomes a double-digit per-share grower. Q1 2026 showed it: adjusted earnings rose 18% to $1.6 billion, but adjusted EPS rose 23% to $2.42 (beating the $2.27 estimate by nearly 7%), with the buyback turning business growth into faster per-share growth. Adjusted ROE hit 17%, the top of the 15% to 17% target.

The operating engine behind New Frontier is genuinely broad-based, which is what makes the EPS target credible rather than financially engineered. Adjusted premiums, fees, and other revenues rose 10% in the quarter, and the growth is spread across segments. Retirement and Income Solutions is a standout: the 10-K notes its "adjusted premiums, fees and other revenues for the year ended December 31, 2025 increased $3.7 billion, or 43%," driven by "growth in our pension risk" transfer business, which is the secular tailwind of corporations offloading pension obligations to insurers. Group Benefits, the largest segment, is a sticky employer-sold book with structural demand. Management called the 23% EPS growth "balanced and repeatable across all operating segments," and the direct expense ratio of 11.9% beat the annual target.

The valuation leaves room for a steady re-rating. The stock trades around 8.5 times forward earnings against FY2026 consensus EPS near $9.81 (up about 12%), and the relative-valuation frame lands near $98, above the roughly $86 price. The dividend of $0.5675 quarterly (about a 2.65% yield) plus the buyback delivers a total shareholder return near 8% annually before any multiple expansion. Analysts carry a Buy consensus with targets near $93 to $95. The bull case is a high-ROE, capital-returning insurer hitting its plan, where the per-share growth the static models cannot price is doing the heavy lifting.

Bear Case

The honest framing is the model disagreement, because for MetLife the valuation methods split sharply and the conservative ones deserve respect. The two-stage dividend model lands near $20.

The business is more cyclical and rate-sensitive than the smooth EPS line suggests. A life and retirement insurer's earnings depend heavily on investment yields, credit spreads, and equity markets, and the pension-risk-transfer growth that drove RIS up 43% is lumpy deal flow, not recurring organic growth, so a slow year of pension deals would remove a major contributor. The reported results also carry actuarial assumption changes (the filing notes a favorable $27 million item from an actuarial assumption review), the kind of adjustment that can swing the other way and that makes any single quarter a less reliable guide to run-rate earnings than the headline implies.

The per-share story has a ceiling. Much of the double-digit EPS growth comes from buybacks, and buybacks at a price the conservative frames call expensive are a less attractive use of capital than buybacks at a discount to book. The stock already trades near analyst targets (a $93 average against an $86 price is only modest upside), and one source notes "limited near-term upside" with the total return resting mostly on the roughly 8% from dividends and buybacks. The bear conclusion is that MetLife is a fine business executing well, but at a price the book-anchored models say is full, the return is the capital return and little more, with downside if rates, credit, or markets turn against a leveraged, float-funded balance sheet.

Valuation

MetLife is valued as a financial, on book value and return on equity rather than an operating multiple, and the models disagree by a wide margin. The relative-valuation frame is the outlier on the high side at about $98, above the roughly $86 price, and the blended X-ray lands near $65. The system characterizes the price as supported by asset-based and relative-multiple value while earnings-power and growth-DCF say expensive, an elevated but value-anchored profile.

The reconciliation is the same one that applies to any high-ROE insurer trading above book: the asset frames value the existing book conservatively, while the relative and earnings frames credit the forward ROE and EPS growth. MetLife's adjusted ROE of 17% sits at the top of its target, and the New Frontier plan calls for double-digit EPS growth, so the case for paying above the book-anchored frames rests on that ROE and growth persisting. The cost of equity in the solve is about 10.2%, and the sensitivity is modest at about 2 points per point of cost of capital.

The practical read: on tangible book MetLife looks expensive, on forward earnings (about 8.5 times) it looks reasonable, and the truth is in whether the 15% to 17% ROE and the buyback-driven EPS growth hold. If they do, the relative frame near $98 and the analyst targets near $93 are the right guide. If rates, credit, or pension-deal flow disappoint, the book-anchored frames in the $30s to $40s are the more honest anchor, and the price has more downside than the modest analyst upside suggests. The roughly 2.65% dividend plus buyback is the return collected while that resolves.

Catalysts

Q1 2026 was a clean beat. Adjusted earnings rose 18% to $1.6 billion and adjusted EPS rose 23% to $2.42, beating the $2.27 estimate by nearly 7%, with adjusted ROE of 17% (top of the 15% to 17% target) and a direct expense ratio of 11.9% that beat the annual goal. Net income was $1.1 billion ($1.74 per share). Adjusted premiums, fees, and other revenues grew 10%.

Management reaffirmed full-year guidance and credited the New Frontier strategy, which targets double-digit adjusted EPS growth and 15% to 17% adjusted ROE, describing the quarter's growth as balanced and repeatable across segments. FY2026 consensus EPS sits near $9.81, up about 12%.

Capital return is the steady catalyst: a $0.5675 quarterly dividend (about a 2.65% yield) plus an active buyback (about $600 million, or 1.15% of shares, repurchased over a recent four-month window). The share count is shrinking about 5.7% a year.

Analyst sentiment is constructive but sees limited near-term upside: a Buy consensus with an average target near $93 (Mizuho at $95, Barclays at $93), close to the current price. The swing factors are investment yields and credit conditions, the pace of pension-risk-transfer deal flow in RIS, equity-market levels, and continued execution against the New Frontier ROE and EPS targets.

Peer Cohorts (Per Segment, With Filing Citations)

Group Benefits (reported)

Retirement and Income Solutions (RIS) (reported)

MIM (MetLife Investment Management) (reported)

Core business (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

View the full interactive MET report on boothcheck